Abstract
We begin by reviewing the first characterization of fragile X syndrome, which ultimately led to cloning of the FMR1 gene. Discovery of the molecular basis of this disorder, including expansion of a trinucleotide repeat, gave insight not only into fragile X syndrome but also into the premutation syndromes. Features of fragile X syndrome are discussed including the patient phenotype down to the neuronal phenotype. The domain features of the fragile X mental retardation protein FMRP are described, as are the mRNAs bound by FMRP and the role of post-translational modifications as regulators of FMRP function. The relatively new role of FMRP in progenitor cells is reviewed, as is FMRP localization in cells and how FMRP is regulated by glutamatergic signaling in the brain. Understanding how metabotropic glutamate receptors impact FMRP has led to novel therapeutic approaches in treating this disorder.
Keywords: Fragile X, FMRP, RNA binding protein, posttranslational modification, trinucleotide repeat disorder, translation regulation, Fragile X Syndrome, FXS, CGG, FMR1 coding sequence.
Current Protein & Peptide Science
Title:Fragile X Mental Retardation Protein: Past, Present and Future
Volume: 13 Issue: 4
Author(s): Miri Kim and Stephanie Ceman
Affiliation:
Keywords: Fragile X, FMRP, RNA binding protein, posttranslational modification, trinucleotide repeat disorder, translation regulation, Fragile X Syndrome, FXS, CGG, FMR1 coding sequence.
Abstract: We begin by reviewing the first characterization of fragile X syndrome, which ultimately led to cloning of the FMR1 gene. Discovery of the molecular basis of this disorder, including expansion of a trinucleotide repeat, gave insight not only into fragile X syndrome but also into the premutation syndromes. Features of fragile X syndrome are discussed including the patient phenotype down to the neuronal phenotype. The domain features of the fragile X mental retardation protein FMRP are described, as are the mRNAs bound by FMRP and the role of post-translational modifications as regulators of FMRP function. The relatively new role of FMRP in progenitor cells is reviewed, as is FMRP localization in cells and how FMRP is regulated by glutamatergic signaling in the brain. Understanding how metabotropic glutamate receptors impact FMRP has led to novel therapeutic approaches in treating this disorder.
Export Options
About this article
Cite this article as:
Kim Miri and Ceman Stephanie, Fragile X Mental Retardation Protein: Past, Present and Future, Current Protein & Peptide Science 2012; 13 (4) . https://dx.doi.org/10.2174/138920312801619420
DOI https://dx.doi.org/10.2174/138920312801619420 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biomarkers and Cellular Signal Detection for Alzheimer’s Disease, Stroke, and Immune System Mediated Disorders
Current Neurovascular Research Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors
Current Pharmaceutical Design A Role for Calcineurin in Alzheimers Disease
Current Neuropharmacology On the Interaction of β-Amyloid Peptides and α7-Nicotinic Acetylcholine Receptors in Alzheimer’s Disease
Current Alzheimer Research Review of Synthesis, Assay, and Prediction of β and γ-secretase Inhibitors
Current Topics in Medicinal Chemistry Biosafety of Recombinant Adeno-associated Virus Vectors
Current Gene Therapy NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Peripheral Kynurenine Metabolism in Focal Dystonia
Medicinal Chemistry Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin
Current Drug Abuse Reviews Mood, Memory and Movement: An Age-Related Neurodegenerative Complex?
Current Aging Science Poloxamer 188 (P188), A Potential Polymeric Protective Agent for Central Nervous System Disorders: A Systematic Review
Current Neuropharmacology Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement
Current Pharmaceutical Design Modulation of Cell Death in Age-Related Diseases
Current Pharmaceutical Design Tetramethoxyluteolin for the Treatment of Neurodegenerative Diseases
Current Topics in Medicinal Chemistry A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates
Current Neuropharmacology RAGE, Diabetes, and the Nervous System
Current Molecular Medicine The Contribution of Cerebral Vascular Neuropathology to Mild Stage of Alzheimer’s Dementia Using the NACC Database
Current Alzheimer Research TARDBP Ala382Thr Mutation in Multiple Sclerosis: A Possible Role in Brain Atrophy
Current Medical Imaging Huntingtons Disease: The Value of Transcranial Meganetic Stimulation
Current Medicinal Chemistry Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson’s Disease
Current Medicinal Chemistry